Kimia biosciences Limited has announced the resignation of Mr. Kaku Vijaya Shekhar Reddy from his position as Additional Director in the category of Executive Director. The pharmaceutical company informed BSE Limited about this corporate governance change through a regulatory filing dated February 19, 2026.

Director Resignation Details

The resignation became effective from February 18, 2026, with the company accepting it from the closure of business hours on February 19, 2026. Mr. Reddy cited personal reasons for his departure from the executive position.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Pallavi Garg signed the regulatory filing, ensuring compliance with disclosure requirements under SEBI Master Circular No. SEBI/HO/CFD/PoD2/ClR/P/0155 dated November 11, 2024.

Director's Service Tenure

According to the resignation letter, Mr. Reddy had been serving as Director Technical since December 5, 2025. In his resignation communication addressed to Managing Director Mr. Sameer Gool, he mentioned that unforeseen personal circumstances necessitated stepping away from his professional responsibilities. He requested immediate release from his duties while expressing gratitude for the opportunity to serve the pharmaceutical company.

Company Information

Kimia Biosciences Limited operates from its registered office and works located at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. The company also maintains a corporate office at Aggarwal Millennium Tower-II in New Delhi's Netaji Subhash Place, Pitampura.

Kimia Biosciences Limited has dispatched its postal ballot notice to shareholders on February 18, 2026, seeking approval for the re-appointment of Managing Director Sameer Goel. The company had earlier approved the postal ballot process following board meetings held on February 14 and February 16, 2026, where it modified the original notice by withdrawing one agenda item.

Postal Ballot Process and Timeline

The postal ballot notice has been dispatched to all eligible shareholders whose email addresses are registered with the company or depositories as of the cut-off date of February 6, 2026. The company is conducting the postal ballot exclusively through electronic voting in compliance with MCA circulars and SEBI regulations.

Managing Director Re-appointment Details

The sole agenda item in the revised postal ballot seeks shareholder approval for the re-appointment of Mr. Sameer Goel (DIN: 00161786) as Managing Director for a five-year term. The board had earlier withdrawn the regularisation of Mr. Kaku Vijaya Shekhar Reddy as Whole Time Director from the postal ballot agenda.

Background and Qualifications

Mr. Sameer Goel, aged 52 years, is a Delhi University Commerce graduate with extensive experience in the Indian API market. As the founder of Kimia Biosciences Limited, he has established the company as a significant player in bulk drugs addressing various high-potential therapeutic segments. He possesses strong capabilities in business development, product development, strategic marketing, and operations management.

E-voting Process and Compliance

Shareholders can cast their votes through NSDL's e-voting platform at www.evoting.nsdl.com . The company has appointed Mr. Maghisuddin, proprietor of M/s M & Company, as the scrutinizer to oversee the e-voting process. The postal ballot notice is available on the company's website at www.kimiabiosciences.com and on BSE's website.

The resolution, if passed by the requisite majority, will be deemed to have been passed on March 21, 2026. The scrutinizer will submit the report within two working days of the conclusion of remote e-voting, and results will be declared and communicated to the stock exchange where the company's shares are listed.